Clinical Trials

GastrointestinalGenitourinaryHead & NeckThoracic

310 enrolled

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Head and Neck Neoplasms, Pancreatic Neoplasms

NCT06657144 2026-04-06

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

154 enrolled

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT07277413 2026-04-03

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

GastrointestinalGenitourinaryOther solid neoplasmThoracic

260 enrolled

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Mesothelioma, Neoplasm Metastasis, Recurrence

NCT05568095 2026-04-02

STAR-221

Phase 3 Active not recruiting

1,040 enrolled

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT07221149 2026-04-02

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Phase 2/3 Recruiting

690 enrolled

Phase 2 Active not recruiting

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT05329766 2026-03-30

EDGE-Gastric

332 enrolled

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT05411133 2026-03-19

Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients

Phase 1 Completed

33 enrolled

Adenocarcinoma Of Esophagus, Gastrointestinal Neoplasms, Liver Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma

NCT05954312 2026-03-18

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

290 enrolled

Adenocarcinoma Of Esophagus, Neoplasms

NCT04900818 2026-03-05

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

330 enrolled

Phase 3 Active not recruiting

Adenocarcinoma Of Esophagus, Biliary Tract Neoplasms, Neoplasm Metastasis, Stomach Neoplasms

NCT06356311 2026-02-27

TroFuse-015

450 enrolled

Adenocarcinoma Of Esophagus

NCT07432295 2026-02-25

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

Phase 2 Recruiting

180 enrolled

Phase 2 Active not recruiting

Adenocarcinoma Of Esophagus, Neoplasm Metastasis, Stomach Neoplasms

NCT04430738 2026-02-24

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

40 enrolled 67 charts

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT06005493 2026-02-24

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

Phase 1/2 Recruiting

280 enrolled

DermatologicGastrointestinalGynecologicHead & NeckThoracic

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT07023731 2026-02-19

A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

Phase 1/2 Recruiting

159 enrolled

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Gallbladder Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT07334119 2026-02-19

Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

BreastGastrointestinalGenitourinaryGynecologicThoracic

60 enrolled

Adenocarcinoma Of Esophagus, Carcinoma, Ovarian Epithelial, Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT06330064 2026-02-12

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

Phase 2 Recruiting

520 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Recurrence, Colorectal Neoplasms, Endometrial Neoplasms

NCT07182149 2026-02-12

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

BreastGastrointestinalGynecologicHead & Neck

150 enrolled

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06560645 2026-02-02

A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

42 enrolled

GastrointestinalThoracic

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06266299 2026-01-28

A Study of KK2269 in Adult Participants With Solid Tumors

101 enrolled

GastrointestinalThoracic

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05977322 2025-12-24

A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.

GastrointestinalGynecologicHead & NeckThoracic

24 enrolled

CNSGastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Glioblastoma, Pancreatic Neoplasms, Stomach Neoplasms

NCT06549816 2025-12-15

A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors

Phase 1 Completed

6 enrolled

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT03983954 2025-11-28

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

Phase 1 Active not recruiting

120 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05252416 2025-11-28

(VELA) Study of BLU-222 in Advanced Solid Tumors

GastrointestinalGynecologicSarcoma

50 enrolled

Adenocarcinoma Of Esophagus, Carcinosarcoma, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT05104567 2025-09-24

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)

Phase 2 Completed

138 enrolled 32 charts

2,031 enrolled 19 charts 2 FDA

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Carcinoma, Hepatocellular, Stomach Neoplasms, Colorectal Neoplasms

NCT02872116 2025-08-07

CheckMate649

Phase 3 Completed

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT06030180 2025-06-27

PR-0410

Phase NA Completed

566 enrolled

Adenocarcinoma Of Esophagus, Barrett Esophagus

NCT04499924 2025-01-22

MOUNTAINEER-02

Phase 2/3 Completed

17 enrolled 23 charts

Phase 3 Active not recruiting

Adenocarcinoma Of Esophagus

NCT04210115 2024-11-15

KEYNOTE 975

703 enrolled

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT03809624 2024-10-23

PDL1x41BB

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

160 enrolled

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Oropharyngeal Neoplasms, Stomach Neoplasms

NCT04683939 2024-10-02

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors

Phase 1/2 Terminated

13 enrolled 24 charts

Adenocarcinoma Of Esophagus, Biliary Tract Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma

NCT05591053 2024-02-21

Utility and Usability of ActivSight™ Laser Speckle Imaging in Visualization of Tissue Perfusion and Blood Flow During Esophageal Surgery in Humans

Phase NA Unknown

70 enrolled

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Diseases, Esophageal Neoplasms, Neoplasms

NCT04293458 2023-01-25

ESOGUARDBE1

Phase NA Completed

145 enrolled

Adenocarcinoma Of Esophagus, Barrett Esophagus

NCT04295811 2023-01-25

ESOGUARDBE2

Phase NA Unknown

470 enrolled

Adenocarcinoma Of Esophagus, Barrett Esophagus

NCT04060342 2022-08-18

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

BreastGastrointestinalGenitourinaryHead & NeckThoracic

61 enrolled

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03789617 2022-07-11

A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies

Phase 1/2 Unknown

72 enrolled

GastrointestinalLymphoid

Adenocarcinoma Of Esophagus, Lymphoma, Stomach Neoplasms

NCT00573131 2022-06-22

Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer

137 enrolled 9 charts

GastrointestinalLymphoidSarcomaThoracic

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Neoplasms

NCT03365791 2022-05-27

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Phase 2 Completed

76 enrolled 14 charts

Adenocarcinoma Of Esophagus, Lymphoma, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Small Cell Lung Carcinoma

NCT00101972 2022-02-22

RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma

Phase 1 Completed

53 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Carcinoma, Ovarian Epithelial, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Vaginal Neoplasms, Endometrial Neoplasms

NCT03122548 2019-04-04

Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers

5 enrolled 11 charts

Adenocarcinoma Of Esophagus, Digestive System Diseases, Esophageal Neoplasms, Gastrointestinal Diseases, Stomach Diseases, Stomach Neoplasms

NCT02638909 2018-04-02

Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies

4 enrolled

Adenocarcinoma Of Esophagus, Cholangiocarcinoma

NCT02016534 2017-07-02

Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors

60 enrolled